Key facts
- Centaur Robotics’s last known valuation is $6.0M (Aug 2025).
- It has raised $3.8M; the latest was Later Stage VC ($210K) in Aug 2025.
- Notable investors include Innovate UK, Future Planet Capital, UK Research and Innovation, Midlands Engine Investment Fund, Future Planet Capital Regional — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Centaur Robotics
- ·The full record, as it builds
Funding rounds
No funding rounds for Centaur Robotics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Centaur Robotics
Developer of an AI (Artificial Intelligence)-driven genomics platform designed for diagnosis, treatment, and prevention of all complex diseases, including cancer, heart disease, and neurological diseases. The company offers products developed by a proprietary technology tool that analyzes different parts of deoxyribonucleic acid that reflect an inherited predisposition to disease and the risk acquired from living, transforming precision medicine, enabling caretakers and hospitals to transform the lives of those with mobility issues.
- Sector
- Healthcare
- HQ
- Solihull, United Kingdom
- Founded
- 2014
- Employees
- 6
- Website
- centaurrobotics.com/
- Ownership
- Privately Held (backing)
Centaur Robotics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Centaur Robotics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Centaur Robotics in its N-PORT filings yet. We sweep new filings monthly.